KK Shah Hospitals Limited is a rapidly expanding multi-specialty healthcare provider headquartered in **Ratlam, Madhya Pradesh**. Originally established as a proprietorship (**M/s Shah Hospital**), the company transitioned to a public limited entity in **2022** and successfully listed on the **BSE SME Platform** in **November 2023**. The company provides a comprehensive range of diagnostic, surgical, and rehabilitative services, positioning itself as a technology-driven healthcare leader in the regional markets of Madhya Pradesh and Rajasthan. --- ### **Corporate Evolution and Capital Structure** The company’s transition from a private practice to a listed corporate entity was formalized via a Business Transfer Agreement on **December 31, 2022**, through which it acquired the entire running business and assets of the promoter’s proprietorship. * **IPO and Listing:** The company issued **1,950,000 Equity Shares** at **Rs. 45 per share** in **November 2023**. * **Capital Position (as of March 31, 2024):** * **Authorised Capital:** **Rs. 7,00,00,000** (75,00,000 shares of Rs. 10 each). * **Paid-up Capital:** **Rs. 6,80,85,420** (68,08,542 shares of Rs. 10 each). * **Organizational Structure:** The company operates as a standalone entity with **no holding, subsidiary, joint venture, or associate companies**. * **Asset Governance:** Management maintains a strict physical verification cycle for **Property, Plant, and Equipment** once every **three years**. --- ### **Clinical Specializations and Technological Infrastructure** KK Shah Hospitals differentiates itself through the integration of advanced medical technology within the SME healthcare segment, focusing on high-precision surgical outcomes. #### **1. Orthopedic Excellence & Robotics** The hospital is a regional pioneer in robotic surgery, utilizing the **VELYS Robotic Assisted System**. This **4th generation robotic system** is dedicated to **Knee Replacement surgery**, offering: * Enhanced surgical precision and joint alignment. * Minimal invasive procedures resulting in **less blood loss**. * **Faster recovery times** for patients compared to traditional methods. #### **2. Ophthalmology and Vision Care** Comprehensive eye care is provided at both the **Ratlam** and **Thandla** facilities. The department is equipped with specialized diagnostic and surgical tools, including: * **OERTLI Catarex 3 Easy:** Advanced Phaco technology for cataract surgeries. * **Diagnostic Suite:** AR-K, Slit lamp with imaging systems, Lensometers, Vision LED, and Indirect Ophthalmoscopes. * **Applanation Tonometers** for precise intraocular pressure measurement. #### **3. Diagnostic and General Surgery** The company maintains a robust diagnostic backbone, including a **high-technology CT Scan Machine** for full-body health solutions. The general surgery department focuses on minimally invasive tools to improve clinical throughput. --- ### **Strategic Expansion and Geographic Footprint** The company is executing an aggressive growth strategy to capture underserved demand in rural and semi-urban clusters through a "Hub and Spoke" model. * **Facility Scaling:** * **Thandla (Jhabua, M.P.):** Launched a new **65-bed** multi-specialty hospital in **April 2024**. * **Ratlam (M.P.):** Expanded the core facility from **35 to 50 beds** in **July 2025** to handle increased patient inflow. * **Peripheral OPD Network:** In **February 2025**, the company launched three specialized Outpatient Departments (OPDs) to act as referral feeders: * **Kushalgarh (Rajasthan):** Orthopaedic focus. * **Jhabua (M.P.):** General Surgery and Orthopaedics. * **Petlawad (M.P.):** Gynaecology and Orthopaedics. --- ### **Institutional Healthcare and Government Empanelments** A significant driver of patient volume is the company’s integration into national healthcare schemes and corporate partnerships. | Entity / Scheme | Date of Empanelment | Target Beneficiaries | | :--- | :--- | :--- | | **Ayushman Bharat (PM-JAY)** | **March 2026** | National flagship scheme for low-income families. | | **Railway Hospital (Western Railway)** | **January 2026** | Localized care for Railway employees in Ratlam. | | **Indian Railways (National)** | **January 2026** | National-level authorization for railway personnel. | --- ### **Financial Performance and Shareholder Returns** Since its listing, the company has demonstrated exponential growth in both revenue and profitability. | Metric | FY 2023-24 | FY 2022-23 | Growth (%) | | :--- | :--- | :--- | :--- | | **Total Turnover** | **Rs. 6.88 Crore** | **Rs. 2.12 Crore** | **224.53%** | | **Net Profit After Tax (PAT)** | **Rs. 60.72 Lakhs** | **Rs. 21.81 Lakhs** | **178.40%** | * **Dividend Policy:** For FY 2023-24, the Board recommended a dividend of **Rs. 0.50 per equity share** (**5%**). * **Profitability Trend:** PAT increased by **Rs. 38.91 Lakhs** year-on-year, reflecting improved operational efficiencies and higher-margin robotic procedures. --- ### **Capital Allocation and IPO Proceeds Utilization** In **February 2025**, the company strategically reallocated its **IPO proceeds** to prioritize high-demand robotic technology over certain diagnostic equipment. * **Reallocation of ₹3.58 Crore:** Funds were diverted to procure the **VELYS Robotic Assisted System**. * **Funding Sources for Reallocation:** * **₹3.21 crore** diverted from the original **MRI Scanner** budget. * **₹23.51 Lakhs** from cancelled **ERCP** and **Thunder Beat** machine orders. * **₹13.28 Lakhs** from surplus funds in the **CT Scanner** budget. * **Future Capex:** The company intends to fund the eventual purchase of the **MRI Scanner** through **Bank/NBFC loans** once the full payment becomes due. As of **February 2025**, **₹5.51 crore** in IPO proceeds remained unutilized. --- ### **Risk Management and Mitigation Framework** The company operates under a formal **Risk Assessment and Minimization Procedure** overseen by the Board. | Risk Category | Description and Mitigation | | :--- | :--- | | **Project Execution** | Delays in acquiring high-end equipment (e.g., MRI) are mitigated by phased bank financing and prioritizing high-ROI robotic systems. | | **Cybersecurity** | Increasing threats to patient data and hospital networks; addressed through ongoing IT infrastructure updates. | | **Regulatory** | Exposure to shifts in **Tax Laws** and **Information Technology & Security Laws**. The company maintains a dedicated compliance review process. | | **Liquidity** | While the company can meet liabilities within **one year**, it focuses on cost reduction and productivity to ensure long-term debt servicing. | | **Technological** | Risk of obsolescence is managed by pivoting toward **4th generation robotics** and advanced Phaco technology to maintain a competitive edge. |